コンテンツへスキップ
Merck
すべての画像(1)

主要文書

安全性情報

476485

Sigma-Aldrich

PKA Inhibitor 14-22 Amide, Cell-Permeable, Myristoylated

PKA Inhibitor 14-22 Amide is myristoylated at the N-terminus that enhances its cell-permeability. The non-myristoylated version is shown to be a specific inhibitor of PKA (Ki = 36 nM).

別名:

PKA Inhibitor 14-22 Amide, Cell-Permeable, Myristoylated, PKI 14-22 Amide, Cell-Permeable, Myristoylated Protein Kinase A Inhibitor Amide 14-22, Cell-Permeable, Myr-GRTGRRNAI-NH₂, Protein Kinase A Inhibitor 14-22 Amide, PKA Inhibitor XIII

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C53H100N20O12
分子量:
1209.49
UNSPSCコード:
12352200
NACRES:
NA.77

品質水準

100

アッセイ

≥95% (HPLC)

フォーム

lyophilized

メーカー／製品名

Calbiochem®

保管条件

OK to freeze
desiccated (hygroscopic)

溶解性

water: 1 mg/mL

輸送温度

ambient

保管温度

−20°C

詳細

Heat-stable protein kinase inhibitor (PKI) peptide sequence (14 - 22) that has been myristoylated at the N-terminus, enhancing its cell-permeability. The non-myristoylated version of this peptide is a highly specific inhibitor (Ki = 36 nM) of cAMP-dependent protein kinase.
Heat-stable protein kinase inhibitor (PKI) peptide sequence (14-22) that has been myristoylated at the N-terminus, enhancing its cell-permeability. The non-myristoylated version of this peptide is a highly specific inhibitor (Ki = 36 nM) of cAMP-dependent protein kinase (PKA).

生物化学的／生理学的作用

Cell permeable: yes
Primary Target
cAMP-dependent protein kinase
Product does not compete with ATP.
Reversible: no
Target Ki: 36 nMf or cAMP-dependent protein kinase

警告

Toxicity: Standard Handling (A)

シーケンス

Myr-N-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-NH₂

物理的形状

Supplied as a trifluoroacetate salt.

再構成

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

その他情報

Paman, K., et al. 1998. J. Lipid Res. 39, 1091.
Rimon, G., and Rubin M. 1998. Biochim. Biophys. Acta 1380, 289.
Harris, T.E., et al. 1997. Biochem. Biophys. Res. Commun. 232, 648.
Muniz, M., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 14461.
Zoukhri, D., et al. 1997. Am. J. Physiol. 272, C263.
Eichholtz, T., et al. 1993. J. Biol. Chem.268, 1982.
Ward, N.E. and O’Brian, C.A. 1993. Biochemistry32, 11903.
Walsh, D.A. and Glass, D.B. 1991. Methods Enzymol. 201, 304.
Glass, D.B., et al. 1989. J. Biol. Chem.264, 8802.

法的情報

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類コード

11 - Combustible Solids

WGK

WGK 1

引火点(°F)

Not applicable

引火点(℃)

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

476485-500UG:
476485-UG:

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Slide 1 of 7

1 of 7

PKA Inhibitor Cocktail

Sigma-Aldrich

20-114

PKA Inhibitor Cocktail

KT 5720 ≥98% (HPLC), powder

Sigma-Aldrich

K3761

KT 5720

H-89 二塩酸塩 水和物 ≥98% (HPLC), powder

Sigma-Aldrich

B1427

H-89 二塩酸塩 水和物

LRE1 ≥98% (HPLC)

Sigma-Aldrich

SML1857

LRE1

Casein Kinase II Inhibitor VIII The Casein Kinase II Inhibitor VIII controls the biological activity of Casein Kinase II. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Sigma-Aldrich

218860

Casein Kinase II Inhibitor VIII

Autocamtide-2 Related Inhibitory Peptide, Myristoylated The Autocamtide-2 Related Inhibitory Peptide, Myristoylated controls the biological activity of calmodulin-dependent protein kinase II. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Sigma-Aldrich

189482

Autocamtide-2 Related Inhibitory Peptide, Myristoylated

9-Cyclopentyladenine monomethanesulfonate ≥98% (HPLC)

Sigma-Aldrich

C4479

9-Cyclopentyladenine monomethanesulfonate

Duomeng Yang et al.
Communications biology, 5(1), 96-96 (2022-01-27)
Intrinsic cardiac adrenergic (ICA) cells regulate both developing and adult cardiac physiological and pathological processes. However, the role of ICA cells in septic cardiomyopathy is unknown. Here we show that norepinephrine (NE) secretion from ICA cells is increased through activation
Lukasz Buldak et al.
Journal of applied biomedicine, 20(4), 130-140 (2023-01-29)
Statins are primary drugs in the treatment of hyperlipidemias. This group of drugs is known for its beneficial pleiotropic effects (e.g., reduction of inflammatory state). However, a growing body of evidence suggests its diabetogenic properties. The culpable mechanism is not
Akiko Nakayama et al.
JCI insight, 5(23) (2020-12-04)
Atherosclerosis develops preferentially in areas of the arterial system, in which blood flow is disturbed. Exposure of endothelial cells to disturbed flow has been shown to induce inflammatory signaling, including NF-κB activation, which leads to the expression of leukocyte adhesion
Lian-Pan Wu et al.
Acta pharmacologica Sinica, 41(1), 34-46 (2019-09-14)
Abnormal growth of the intimal layer of blood vessels (neointima formation) contributes to the progression of atherosclerosis and in-stent restenosis. Recent evidence shows that the 18-kDa translocator protein (TSPO), a mitochondrial membrane protein, is involved in diverse cardiovascular diseases. In
Petra Muenzner et al.
Cell host & microbe, 27(5), 793-808 (2020-04-15)
Several pathogens suppress exfoliation, a key defense of epithelia against microbial colonization. Common among these pathogens, exemplified by Neisseria gonorrhoeae, is their ability to bind carcinoembryonic antigen-related cell adhesion molecules (CEACAMs). Gonococcal CEACAM engagement triggers the expression of CD105, which
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）